This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.
Patricia Cortazar, MD
Advertisement
Articles by Patricia Cortazar, MD
Advertisement
Latest Updated Articles
- Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives
Published: November 16th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
PEG Hydrogel Reduces Rectal Radiation During Cervical Cancer Therapy
2
Early Detection, Education Are Key to Combat Rising Pancreatic Cancer Cases
3
Examining Developments in Safe Administration of Nuclear Agents
4
Sonrotoclax Earns FDA Priority Review in R/R Mantle Cell Lymphoma
5
